Placebo-Controlled, Double-Blind Study of the Non-Purine-Selective Xanthine Oxidase Inhibitor Febuxostat (TMX-67) in Patients With Hyperuricemia Including Those With Gout in Japan

非布索坦 高尿酸血症 痛风 尿酸 医学 黄嘌呤氧化酶 安慰剂 黄嘌呤氧化酶抑制剂 别嘌呤醇 内科学 不利影响 胃肠病学 药理学 化学 生物化学 病理 替代医学 酶
作者
Naoyuki Kamatani,Fujimori Shin,Toshikazu Hada,Tatsuo Hosoya,Kenjiro Kohri,Nakamura Toshitaka,Takanori Ueda,Yamamoto Tetsuya,Yamanaka Hisashi,Matsuzawa Yuji
出处
期刊:Jcr-journal of Clinical Rheumatology [Lippincott Williams & Wilkins]
卷期号:17 (4): S19-S26 被引量:29
标识
DOI:10.1097/rhu.0b013e31821d36de
摘要

BACKGROUND: : Allopurinol has been widely used for treatment of hyperuricemia, however, it may be associated with various adverse effects. Febuxostat has been identified as a potentially safe and efficacious alternative. OBJECTIVES: : A multicenter study with randomized, placebo-controlled, double-blind, parallel-group comparison was carried out to evaluate the efficacy and safety of febuxostat in 103 patients with hyperuricemia (including patients with gout) in Japan. METHODS: : Subjects were treated with febuxostat (20 or 40 mg/d) or a placebo for 8 weeks. The variables evaluated were the percentage of patients achieving serum uric acid levels 6.0 mg/dL or less and the percent change in serum uric acid levels after 8 weeks. RESULTS: : The percentage of patients achieving serum uric acid levels 6.0 mg/dL or less after 8 weeks was 91.2% in the febuxostat 40-mg/d group, 45.7% in the 20-mg/d group, and 0.0% in the placebo group. The percent changes in serum uric acid levels after 8 weeks were -44.9% in the febuxostat 40-mg/d group, -28.9% in the 20-mg/d group, and -0.6% to -0.5% in the placebo group. No severe or medically significant adverse reaction attributable to febuxostat was noted, and there was no event that could pose a clinical problem. The efficacy did not differ depending on the presence/absence of gout history. CONCLUSIONS: : These results suggest that febuxostat (20 or 40 mg/d) is useful as a new means of treating hyperuricemia and is capable of reducing serum uric acid levels to 6.0 mg/dL or less (goal of treatment) with high safety regardless of the presence/absence of gout history.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
lawliet发布了新的文献求助10
1秒前
1秒前
lmm完成签到,获得积分10
1秒前
2秒前
Tutor发布了新的文献求助10
2秒前
2秒前
kirito完成签到,获得积分20
3秒前
刘66发布了新的文献求助10
3秒前
啦啦啦发布了新的文献求助10
4秒前
5秒前
5秒前
5秒前
丘比特的应助被ZHAO采纳,获得10
5秒前
5秒前
6秒前
莉莉丽发布了新的文献求助200
6秒前
haibo发布了新的文献求助10
6秒前
蜜果羹完成签到 ,获得积分10
7秒前
7秒前
木子发布了新的文献求助10
7秒前
柔弱紊完成签到,获得积分10
8秒前
8秒前
北海章完成签到,获得积分10
8秒前
专业海域完成签到,获得积分20
9秒前
唔唉外完成签到,获得积分10
9秒前
sugkook发布了新的文献求助10
9秒前
9秒前
Ma发布了新的文献求助10
10秒前
娇情儿发布了新的文献求助10
10秒前
10秒前
柔弱紊发布了新的文献求助10
10秒前
zxp的应助被乐观的冬天采纳,获得50
11秒前
郭竞阳发布了新的文献求助10
12秒前
失眠善若完成签到,获得积分10
13秒前
打打的应助被公主抡大锤采纳,获得10
14秒前
14秒前
14秒前
所所的应助被霍小怂采纳,获得10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8164445
求助须知:如何正确求助?哪些是违规求助? 9558283
关于积分的说明 21744871
捐赠科研通 7754979
什么是DOI,文献DOI怎么找? 3428582
关于科研通互助平台的介绍 2553119
邀请新用户注册赠送积分活动 2473142